/MPSYF

MPSYF Stock - MorphoSys AG

Q: What is the analyst price target for MPSYF?

Analyst price target information is not currently available for MPSYF.

Q: What is MPSYF's market cap?

Market capitalization information is not currently available for MPSYF.

Healthcare|Biotechnology|OTC

$73.27+2.10%

+$1.51 (+2.10%) • Nov 21

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $80.60

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for MPSYF

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2019

FY2020

FY2021

FY2022

FY2023

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.66

52W High$73.27

52W Low$25.56

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2023	FY2022	FY2021	FY2020	FY2019
Revenue	$238.28M	$278.27M	$179.60M	$327.70M	$71.76M
Gross Profit	$179.92M	$229.65M	$147.40M	$318.52M	$59.67M
Gross Margin	75.5%	82.5%	82.1%	97.2%	83.2%
Operating Income	$-252,475,802	$162.26M	$-277,600,000	$119.41M	$-105,120,108
Net Income	$-189,734,199	$-151,057,591	$-514,500,000	$97.89M	$-103,014,058
Net Margin	-79.6%	-54.3%	-286.5%	29.9%	-143.6%
EPS	$-1.38	$-1.10	$-3.85	$0.75	$-0.81

Company Overview

MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The company also develops Pelabresib, a small molecule that is in Phase II clinical trial to treat myelofibrosis; Felzartamab, an antibody directed against CD38, which is in Phase I/II clinical trials for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease; and CPI-0209, a small molecule that is in Phase I/II designed to promote anti-tumor activity by inhibiting EZH2. In addition, it develops Gantenerumab, an antibody for the treatment of Alzheimer's diseases through its pharmaceutical partners; Otilimab, an antibody for rheumatoid arthritis; Tremfya, an antibody to treat psoriasis, psoriatic arthritis, and palmoplantar pustulosis; and MOR210/TJ210, an antibody to treat immuno-oncology and autoimmune diseases. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize felzartamab in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma; a joint collaboration and license agreement with Incyte Corporation to develop and commercialize MorphoSys investigational compound tafasitamab; and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.

Visit Website

Earnings History & Surprises

MPSYF

Beat Rate

50%

Last 16 quarters

Avg Surprise

-13.7%

EPS vs Estimate

Beats / Misses

8/8

Last 12 quarters

Latest EPS

$-2.26

Q3 2024

EPS Surprise History

Q4 22

-138.4%

$-3.60vs$-1.51

Q1 23

+718.5%

$10.39vs$-1.68

Q2 23

+84.0%

$-1.41vs$-8.82

Q3 23

+69.4%

$-2.36vs$-7.72

Q4 23

-63.9%

$-3.69vs$-2.25

Q1 24

+164.6%

$1.34vs$-2.07

Q2 24

-638.4%

$-8.99vs$-1.22

Q3 24

-70.2%

$-2.26vs$-1.33

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q3 2025	Aug 27, 2025	—	—	—	—
Q2 2025	Apr 28, 2025	—	—	—	—
Q1 2025	Mar 11, 2025	—	—	—	—
Q4 2024	Oct 30, 2024	—	—	—	—
Q3 2024	Aug 29, 2024	$-1.33	$-2.26	-70.2%	✗ MISS
Q2 2024	Apr 29, 2024	$-1.22	$-8.99	-638.4%	✗ MISS
Q1 2024	Mar 13, 2024	$-2.07	$1.34	+164.6%	✓ BEAT
Q4 2023	Nov 16, 2023	$-2.25	$-3.69	-63.9%	✗ MISS
Q3 2023	Aug 10, 2023	$-7.72	$-2.36	+69.4%	✓ BEAT
Q2 2023	May 4, 2023	$-8.82	$-1.41	+84.0%	✓ BEAT
Q1 2023	Mar 15, 2023	$-1.68	$10.39	+718.5%	✓ BEAT
Q4 2022	Nov 16, 2022	$-1.51	$-3.60	-138.4%	✗ MISS
Q3 2022	Aug 3, 2022	$-1.92	$-6.85	-256.8%	✗ MISS
Q2 2022	May 4, 2022	$-1.85	$-0.99	+46.5%	✓ BEAT
Q1 2022	Mar 16, 2022	$-2.77	$-11.44	-313.0%	✗ MISS
Q4 2021	Nov 10, 2021	$-2.55	$-3.30	-29.4%	✗ MISS
Q3 2021	Jul 28, 2021	$-1.93	$0.61	+131.6%	✓ BEAT
Q2 2021	May 5, 2021	$-1.37	$-1.27	+7.3%	✓ BEAT
Q1 2021	Mar 15, 2021	$-2.13	$-0.50	+76.5%	✓ BEAT
Q4 2020	Nov 11, 2020	$-1.85	$-2.00	-8.1%	✗ MISS